champc/iStock via Getty Images
Vaxart's (NASDAQ:VXRT) shares rose following the positive results from an early-stage trial of its new oral pill vaccine for norovirus, a more advanced version compared to its first-generation product.
The findings indicate that the second-generation vaccine constructs generated significant improvements